Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1, receptor ligand
- 8 March 1996
- journal article
- Published by Elsevier in Life Sciences
- Vol. 58 (15), 1249-1257
- https://doi.org/10.1016/0024-3205(96)00086-0
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal functionBrain Research, 1995
- The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neuronsLife Sciences, 1995
- Pharmacology of Cannabinoid ReceptorsAnnual Review of Pharmacology and Toxicology, 1995
- (R)-Methanandamide: A Chiral Novel Anandamide Possessing Higher Potency and Metabolic StabilityJournal of Medicinal Chemistry, 1994
- Motor behavior and nigrostriatal dopaminergic activity in adult rats perinatally exposed to cannabinoidsPharmacology Biochemistry and Behavior, 1994
- Downregulation of rat brain cannabinoid binding sites after chronic Δ9-tetrahydrocannabinol treatmentPharmacology Biochemistry and Behavior, 1994
- Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptorJournal of Medicinal Chemistry, 1993
- Motor disturbances induced by an acute dose of Δ9-tetrahydrocannabinol: Possible involvement of nigrostriatal dopaminergic alterationsPharmacology Biochemistry and Behavior, 1993
- Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid ReceptorScience, 1992
- Tetrahydrocannabinol potentiates reserpine-induced hypokinesiaPharmacology Biochemistry and Behavior, 1981